Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Impact of the Kidney Allocation System with Deceased Donor Kidney Utilization at the DSA Level.
W. Ally,² C. Saunders,¹ K. Brayman,² A. Agarwal.²
¹Lifenet Health, Virginia Beach, VA; ²University of Virginia Health System, Charlottesville, VA.
Background: In December 2014, UNOS implemented broad sweeping changes in the new Kidney Allocation System (KAS). Recent summary reports by UNOS suggest that on a…
2016 American Transplant Congress
The Association of Life Expectancy by Resident Zip Code and Kidney Transplant Outcomes – What Is True Baseline Risk?
L. Buccini, D. Goldfarb, E. Poggio, S. Flechner, J. Schold.
Cleveland Clinic, Cleveland, OH.
Many factors beyond traditional clinical risk factors and demographics are associated with outcomes in the general population. These include behavioral, economic, genetic and environmental risks…
2016 American Transplant Congress
Morbid Obesity and Functional Status as Predictors of Surgical Complication After Renal Transplantation.
T. Veasey, J. Fleming, S. Strout, R. Miller, N. Pilch, H. Meadows, C. Mardis, B. Mardis, P. Baliga, J. McGillicuddy, D. Taber.
Medical University of South Carolina, Charleston, SC.
Purpose: Surgical complications after renal transplant may impact patient morbidity and healthcare utilization. Identification of patients at risk would allow for planning allocation of resources…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
¹University of Utah, Salt Lake City, UT; ²University of Southern California, Los Angeles, CA; ³Barnabas Health, West Orange, NJ; ⁴Novartis Pharmaceuticals Corporation, East Hannover, NJ; ⁵California Pacific Medical Center, San Francisco, CA; ⁶Vanderbilt University, Nashville, TN.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…
2016 American Transplant Congress
Short UK Dialysis Does Not Significantly Impact on Live Donor Kidney Allograft Survival.
A. Bentall,^1,2 M. Jesky,^1,2 R. Borrows,^1,2 R. Johnson,³ S. Ball.^1,2
¹Department of Nephrology, University Hospitals Birmingham, Birmingham, United Kingdom; ²School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; ³NHSBT, Bristol, United Kingdom.
Background. The survival advantage of pre-emptive transplantation (Pre-empTx) in live donor kidney transplantation (LDKTx) was reported by Meier-Kreische (Kidney International, 2000). Dialysis practices differ internationally…
2016 American Transplant Congress
Pregnancy Excludes Women from Successful Living Donor Transplantation.
P. Porrett,¹ B. Bromberger,² S. Hashmi,¹ A. Morrison,¹ D. Sawinski.³
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Surgery, Columbia University, New York, NY; ³Medicine, University of Pennsylvania, Philadelphia, PA.
INTRODUCTION Pregnancy-induced sensitization (PIS) is a barrier to the transplantation of women and contributes significantly to gender disparity in transplantation. We hypothesized that this barrier…
2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
¹Hopital Cochin, Paris, France; ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Gilead Sciences Inc, Foster City; ⁴Hôpital Saint Joseph, Marseilles, France; ⁵Hannover Medical School, Hannover, Germany; ⁶Medical University of Vienna, Vienna, Austria.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…
2016 American Transplant Congress
Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection.
R. Pelletier,¹ I. Balazs,² P. Adams,³ P. Steller,³ N. DiPaola,⁴ L. Rankin,³ A. Diez,⁵ M. Henry.¹
¹Surgery/Transplant, The Ohio State University Wexner Medical Center, Columbus, OH; ²Discovery Research, Immucor, Inc, Stamford, CT; ³Tissue Typing, The Ohio State University Wexner Medical Center, Columbus, OH; ⁴Methodist Hospital, Houston, TX; ⁵Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH.
Recent interest in characterizing the complement-fixing ability of post-transplant donor specific alloantibodies (DSA) resulted in the enhancement of luminex solid phase alloantibody assays to determine…
2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57⁺ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
H. Xu, F. Feng, A. Kirk.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…